Bicyclic heterocyclic p-38 kinase inhibitors

Details for Australian Patent Application No. 2004309420 (hide)

Owner Novartis AG

Inventors Lan, Jiong; Lang, Hengyuan; Wang, Jianqiang; Dong, Qing

Agent Davies Collison Cave

Pub. Number AU-B-2004309420

PCT Pub. Number WO2005/063766

Priority 60/532,529 23.12.03 US; 60/575,113 28.05.04 US

Filing date 23 December 2004

Wipo publication date 14 July 2005

Acceptance publication date 30 October 2008

International Classifications

C07D 473/00 (2006.01) Heterocyclic compounds containing purine ring systems

C07D 487/04 (2006.01) Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups

Event Publications

29 June 2006 PCT application entered the National Phase

  PCT publication WO2005/063766 Priority application(s): WO2005/063766

30 October 2008 Application Accepted

  Published as AU-B-2004309420

26 February 2009 Standard Patent Sealed

21 July 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004309421-Definitive endoderm

2004309419-Novel spiroindoline or spiroisoquinoline compounds, methods of use and compositions thereof